THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)

Objectives To evaluate the changes in cytokine profile in MTX-naive patients (pts) with early RA during MTX and ADA+MTX therapy Methods Serum samples from 45 MTX-naive adults with early RA who received MTX (35 woman, mean age 53,5; 46-59,5 years, mean disease duration 7,0; 4,0-11,5 months, mean DAS 28 5,8; 4,9-6,4, RF positive-91%, anti-CCP positive-96%) were analyzed for selected markers of inflammation. The levels of IL-1b, IL-1Pa, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF-basic, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α, VEGF (pg/ml) were tested by multiplex technology xMAP at baseline and weeks 12 and 24 Results After 3 months the efficacy of SC MTX have met the goal (EULAR response) in 23 (51%) of pts (not switching group). Switching to combination with ADA was required in 22 (49%) of pts (switching group). The relations between achievement of LDA or remission according to treatment regimens are shown in the table 1. Table 1 Weeks Parameters Not switching group (n=23) Switching group (n=22) Baseline DAS 28 4,9 (4,3–6,0) 6,1 (5,9–6,8)§ Week 12 DAS 28 3,5 (2,8–3,9)* 5,3 (5,6–5,9)*§ DAS 28 remission/LDA 34,8% 0 Week 24 DAS 28 2,9 (2,1–3,6)* 3,4 (3,2–4,4)* DAS 28 remission/LDA 60,9% 31,8% *p